These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1343 related articles for article (PubMed ID: 9342843)

  • 41. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.
    Imaizumi M; Suzuki H; Yoshinari M; Sato A; Saito T; Sugawara A; Tsuchiya S; Hatae Y; Fujimoto T; Kakizuka A; Konno T; Iinuma K
    Blood; 1998 Jul; 92(2):374-82. PubMed ID: 9657734
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autophagy and Ubiquitin-Mediated Proteolytic Degradation of PML/Rarα Fusion Protein in Matrine-Induced Differentiation Sensitivity Recovery of ATRA-Resistant APL (NB4-LR1) Cells: in Vitro and in Vivo Studies.
    Wu D; Shao K; Zhou Q; Sun J; Wang Z; Yan F; Liu T; Wu X; Ye B; Huang H; Zhou Y
    Cell Physiol Biochem; 2018; 48(6):2286-2301. PubMed ID: 30114705
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The aberrant fusion proteins PML-RAR alpha and PLZF-RAR alpha contribute to the overexpression of cyclin A1 in acute promyelocytic leukemia.
    Müller C; Yang R; Park DJ; Serve H; Berdel WE; Koeffler HP
    Blood; 2000 Dec; 96(12):3894-9. PubMed ID: 11090075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells.
    Rousselot P; Hardas B; Patel A; Guidez F; Gäken J; Castaigne S; Dejean A; de Thé H; Degos L; Farzaneh F
    Oncogene; 1994 Feb; 9(2):545-51. PubMed ID: 8290265
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
    J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha.
    Drach J; McQueen T; Engel H; Andreeff M; Robertson KA; Collins SJ; Malavasi F; Mehta K
    Cancer Res; 1994 Apr; 54(7):1746-52. PubMed ID: 7511050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
    Chen GQ; Shi XG; Tang W; Xiong SM; Zhu J; Cai X; Han ZG; Ni JH; Shi GY; Jia PM; Liu MM; He KL; Niu C; Ma J; Zhang P; Zhang TD; Paul P; Naoe T; Kitamura K; Miller W; Waxman S; Wang ZY; de The H; Chen SJ; Chen Z
    Blood; 1997 May; 89(9):3345-53. PubMed ID: 9129041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro.
    Shiohara M; Dawson MI; Hobbs PD; Sawai N; Higuchi T; Koike K; Komiyama A; Koeffler HP
    Blood; 1999 Mar; 93(6):2057-66. PubMed ID: 10068679
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays.
    Park DJ; Vuong PT; de Vos S; Douer D; Koeffler HP
    Blood; 2003 Nov; 102(10):3727-36. PubMed ID: 12893766
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of differentiation in acute promyelocytic leukemia cells by 9-cis retinoic acid alpha-tocopherol ester (9-cis tretinoin tocoferil).
    Makishima M; Umesono K; Shudo K; Naoe T; Kishi K; Honma Y
    Blood; 1998 Jun; 91(12):4715-26. PubMed ID: 9616170
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
    Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
    Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells.
    Müller S; Miller WH; Dejean A
    Blood; 1998 Dec; 92(11):4308-16. PubMed ID: 9834237
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells.
    Côté S; Rosenauer A; Bianchini A; Seiter K; Vandewiele J; Nervi C; Miller WH
    Blood; 2002 Oct; 100(7):2586-96. PubMed ID: 12239173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein.
    Dermime S; Grignani F; Clerici M; Nervi C; Sozzi G; Talamo GP; Marchesi E; Formelli F; Parmiani G; Pelicci PG; Gambacorti-Passerini C
    Blood; 1993 Sep; 82(5):1573-7. PubMed ID: 8395911
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
    Chen SJ; Chen LJ; Zhou GB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells.
    Nason-Burchenal K; Takle G; Pace U; Flynn S; Allopenna J; Martin P; George ST; Goldberg AR; Dmitrovsky E
    Oncogene; 1998 Oct; 17(14):1759-68. PubMed ID: 9778041
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide.
    Sun Y; Kim SH; Zhou DC; Ding W; Paietta E; Guidez F; Zelent A; Ramesh KH; Cannizzaro L; Warrell RP; Gallagher RE
    Leukemia; 2004 Jul; 18(7):1258-69. PubMed ID: 15116119
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia.
    Niitsu N; Higashihara M; Honma Y
    Exp Hematol; 2002 Nov; 30(11):1273-82. PubMed ID: 12423680
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor.
    Komura N; Ikeda Y; Masuda N; Umezawa Y; Ito K; Kizaki M; Umezawa K
    Leuk Res; 2007 Mar; 31(3):301-13. PubMed ID: 16968653
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination of all-trans retinoic acid with butyric acid and its prodrugs markedly enhancing differentiation of human acute promyelocytic leukemia NB4 cells.
    Chen Z; Wang W; Pan J; Chen L; Xue Y
    Chin Med J (Engl); 1999 Apr; 112(4):352-5. PubMed ID: 11593538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.